Quantcast
Home > Quotes > VSAR
VSAR

Versartis, Inc. Common Stock (VSAR) Quote & Summary Data

$1.375
*  
0.025
1.79%
Get VSAR Alerts
*Delayed - data as of Sep. 25, 2018 9:36 ET  -  Find a broker to begin trading VSAR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VSAR Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.35 / $ 1.40
1 Year Target
3
Today's High / Low
$ 1.40 / $ 1.375
Share Volume
2,142
50 Day Avg. Daily Volume
208,157
Previous Close
$ 1.40
52 Week High / Low
$ 3.05 / $ 1.30
Market Cap
49,830,925
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.05
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.71

Intraday Chart

Shares Traded

Share Volume:
2,142
50 Day Avg. Daily Volume:
208,157

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.05

Trading Range

The current last sale of $1.375 is 5.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.40 $ 3.05
 Low: $ 1.375 $ 1.30

Company Description (as filed with the SEC)

Versartis, Inc. is an endocrine-focused biopharmaceutical company that has been developing a novel long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency, or GHD, an orphan disease. The current standard of care for GHD is daily subcutaneous injections of rhGH. Despite the demonstrated benefits of rhGH therapy, published studies have shown that a majority of patients on a daily rhGH regimen, which requires up to 365 dosing events per year, are not fully compliant and fail to achieve the optimal treatment outcomes. Lack of compliance may be due to the burden of these frequent dosing events. We believe that a long-acting form of rhGH could address this significant unmet need. In our Phase 1a clinical trial in adults, somavaratan demonstrated a half-life at least thirty times longer than daily rhGH and tolerability profile consistent with that of marketed daily rhGH products.  ... More ...  


Risk Grade

Where does VSAR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.40
Open Date:
Sep. 25, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info